Last reviewed · How we verify
Eribulin Injection [Halaven] — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Eribulin Injection [Halaven] (Eribulin Injection [Halaven]) — Institut fuer Frauengesundheit.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Eribulin Injection [Halaven] TARGET | Eribulin Injection [Halaven] | Institut fuer Frauengesundheit | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Eribulin Injection [Halaven] CI watch — RSS
- Eribulin Injection [Halaven] CI watch — Atom
- Eribulin Injection [Halaven] CI watch — JSON
- Eribulin Injection [Halaven] alone — RSS
Cite this brief
Drug Landscape (2026). Eribulin Injection [Halaven] — Competitive Intelligence Brief. https://druglandscape.com/ci/eribulin-injection-halaven. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing